

**EUROPEAN
CURRICULUM VITAE
FORMAT**



PERSONAL INFORMATION

Name

INTINI ROSSANA

Profession

MEDICAL ONCOLOGIST

E-mail

rossana.intini@ioveneto.it

Nationality

Italian

Date of birth

MAY, 8TH 1984

WORK EXPERIENCE

• Dates (from – to)

August, 1st 2017 - present

• Name and address of employer

Director Vittorina Zagonel, MD - Division of Medical Oncology 1, Istituto Oncologico Veneto, Padua

• Type of business or sector

I.R.C.C.S.

• Occupation or position held

Medical Oncologist

• Main activities and responsibilities

Collaboration for clinical management of patients with gastrointestinal cancer within multidisciplinary teams. Management of patients enrolled in clinical trials according to GCP and monitoring support activities. Participation to the design and conduction of national non-sponsored academic clinical and translational trials. Collaboration to the production of scientific works.

• Dates (from – to)

September, 13th 2017 – November, 30th 2018

• Name and address of employer

Casa di Cura di Abano Terme SpA

• Type of business or sector

Hospital

• Occupation or position held

Medical Oncologist consultant

• Main activities and responsibilities

Clinical management of outpatients with gastrointestinal and genitourinary cancer and participation in multidisciplinary teams.

• Dates (from – to)

July 2012 – July 2017

• Name and address of employer

Division of Medical Oncology 1 (Director Vittorina Zagonel, MD) and Division of Medical Oncology 2 (Director Pier Franco Conte, MD) - Istituto Oncologico Veneto, Padua

• Type of business or sector

I.R.C.C.S.

• Occupation or position held

Resident in Medical Oncology

• Main activities and responsibilities

Clinical experience in diagnosis, therapy and palliative care of inpatients and outpatients affected by many cancer types. Clinical and translational research activity with particular interest since December 2015 for gastrointestinal cancer.

RESEARCH EXPERIENCE

	<ul style="list-style-type: none"> • Dates (from – to) 	January 2014 - present
• Name and address of employer		Director Vittorina Zagonel, MD - Division of Medical Oncology 1, Istituto Oncologico Veneto, Padua
<ul style="list-style-type: none"> • Type of business or sector • Occupation or position held 	I.R.C.C.S.	
• Main activities and responsibilities	Co-investigator	Conduction of Industry Sponsored Trials and non-sponsored Academic Trials for gastrointestinal malignancies, palliative care and elderly patients according to GCP and monitoring support activities.
EDUCATION AND TRAINING		
	<ul style="list-style-type: none"> • Dates (from – to) 	July 2012 – July 2017
• Name and type of organisation providing education and training	University of Padua	
• Principal subjects/occupational skills covered	Medical Oncology School	
<ul style="list-style-type: none"> • Title of qualification awarded 	Medical Oncologist	
• Level in national classification	110/110 cum laude. Thesis: "Clinical and molecular understanding of <i>BRAF</i> mutant metastatic colorectal cancer: the BeCool platform, a multicenter cohort study"	
	<ul style="list-style-type: none"> • Dates (from – to) 	February 2012
• Name and type of organisation providing education and training	Order of Physicians-Surgeons and dentist of Bari	
• Principal subjects/occupational skills covered	-	
<ul style="list-style-type: none"> • Title of qualification awarded 	-	
• Level in national classification	Admission to the Order of Physicians-Surgeons and Dentist of Bari (N. 14549)	
	<ul style="list-style-type: none"> • Dates (from – to) 	October 2004 - October 2011
• Name and type of organisation providing education and training	University of Bari "Aldo Moro"	
• Principal subjects/occupational skills covered	Medicine and Surgery Faculty	
<ul style="list-style-type: none"> • Title of qualification awarded 	Degree in Medicine and Surgery (M.D. - Medical Doctor)	
• Level in national classification	110/110 cum laude. Thesis: "The HGF/c-MET system is a regulator of the bone marrow angiogenesis in the multiple myeloma. State of art and clinical and experimental experience in 42 patients"	
	<ul style="list-style-type: none"> • Dates (from – to) 	September 1998 - June 2003

<ul style="list-style-type: none"> • Name and type of organisation providing education and training • Principal subjects/occupational skills covered <ul style="list-style-type: none"> • Title of qualification awarded • Level in national classification 	Scientific High school "Leonardo Da Vinci", Noci (BA)
	High school diploma 97/100

PERSONAL SKILLS AND COMPETENCES

Acquired in the course of life and career but not necessarily covered by formal certificates and diplomas.

MOTHER TONGUE

ITALIAN

OTHER LANGUAGES

English

GOOD

GOOD

GOOD

TECHNICAL SKILLS AND COMPETENCES

With computers, specific kinds of equipment, machinery, etc.

Good command of

- 1) WINDOWS AND MAC OPERATIVE SYSTEMS
- 2) OFFICE PACKAGE: WORD, EXCEL, POWER POINT
- 3) SPSS (STATISTICAL ANALYSIS PROGRAM)
- 4) COMPUTERIZED MEDICAL RECORDS (GALILEO/ONCOSYS PROGRAM)

SCIENTIFIC AFFILIATIONS

Italian Association of Medical Oncology (AIOM)

European Society for Medical Oncology (ESMO)

OTHER INFORMATIONS**SCIENTIFIC ACTIVITY****SCIENTIFIC PUBLICATIONS**

- 1) L. Procaccio, M. Schirripa, M. Fassan, L. Vecchione, F. Bergamo, A. A. Prete, **R. Intini**, C. Manai, V. Dadduzio, A. Boscolo, V. Zagonel, and S. Lonardi. Immunotherapy in Gastrointestinal Cancers. BioMed Research International Volume 2017 (2017).
- 2) F. Battaglin, A. Puccini, **R. Intini**, M. Schirripa, A. Ferro, F. Bergamo, S. Lonardi, V. Zagonel, H.J. Lenz and F. Loupakis. The role of tumor angiogenesis as a therapeutic target in colorectal cancer. Expert Rev Anticancer Ther. 2018 Jan 19:1-16.
- 3) D. Santini, G. Brandi, G. Aprile, M. Russano, S. Cereda, F. Leone, S. Lonardi, L. Fornaro, M. Scartozzi, N. Silvestris, S. Barni, F. Pantano, B. Vincenzi, A. Palloni, G. Frega, M. Casagrande, L. Ferrari, V. Dadduzio, **R. Intini**, R. Filippi, E. Vasile, C. Vivaldi, L. Faloppi, O. Brunetti, M. Reni, M. Aglietta, G. Tonin. Bone metastases in biliary cancers: A multicenter retrospective survey. Journal of Bone Oncology 12 (2018): 33-37.
- 4) F. Loupakis, M. Schirripa, **R. Intini**, F. Bergamo, R. Bertorelle, M. Fassan, V. Dadduzio, S. Merigliano, P. Pilati, E.D.L.Urso, U. Cillo, M. Rugge, S. Lonardi, V. Zagonel. Another Chapter of the *Right Versus Left Story*: Is Primary Tumor Location a Prognostic Feature in RAS Mutant Metastatic Colorectal Cancer? Oncologist. 2018 Aug 17: pii: theoncologist.2018-0180.

MEETING ABSTRACT

- 1) F. Battaglin, F. Bergamo, B. Salmaso, S. Murgioni, **R. Intini**, L. Saadeh, F. Cavallin, C. Manai, F. Urbano, S. Lonardi, C. Lacognata, C. Aliberti, V. Zagonel, C. Castoro, M. Scarpa. Angiogenesis inhibitor bevacizumab and symptomatic anal ulcers in metastatic colorectal cancer patients: A single center experience. J Clin Oncol 35, 2017 (suppl; abstr e15042).
- 2) A. Brunello, S. Lonardi, F. Bergamo, **R. Intini**, L. V. Rumanò, S. Ahcene-Djaballah, P. Fiduccia, A. Lettieri, G. Tierno, A. Pilotto, V. Zagonel. The Oncological Multidimensional Prognostic Index (Onco-Mpi) Helps Predicting Benefits Of Treatment For Patients With Advanced Colorectal Cancer: A Prospective Single Center Study. SIOG16-ABS-1353.
- 3) M. Casagrande, C. Cremolini, G. Zucchelli, F. Bergamo, L. Ferrari, F. Pietrantonio, S. Lonardi, F. Loupakis, G. Masi, N. Pella, **R. Intini**, L. Salvatore, G. Tomasello, F. Pagani, A. Pellino, E. Dell'Aquila, L. Ginocchi, M. Milione, E. Fea, A. Pellegrinelli, A. Falcone. D05FOLFOXIRI plus bevacizumab (bev) as upfront treatment for metastatic colorectal cancer (mCRC) patients (pts) with initially unresectable liver-limited disease (LLD). Ann Oncol (2016) 27 (suppl_4): iv40-iv41.
- 4) V. Catalano, F. Bergamo, C. Cremolini, B. Vincenzi, F. Negri, F. Graziano, P. Giordani, P. Alessandroni, **R. Intini**, L. Rumanò, D. Rossini, B. Borelli, D. Santini, D. Sarti, M. B. Rocchi, S. Lonardi, A. Falcone, V. Zagonel and R. Mattioli. Does bevacizumab plus chemotherapy matter in metastatic colorectal cancer patients with mucinous histology? A multicenter, retrospective analysis on 685 paziente. Ann Oncol 28, 2017 (suppl_6).
- 5) **R. Intini**, F. Loupakis, C. Cremolini, A. Sartore-Bianchi, F. Pietrantonio, N. Pella, D. Santini, L. Rimassa, V. Formica, L. Calvetti, L. Salvatore, L. Antonuzzo, E. De Luca, F. Morano, F. Tosi, R. Moretto, M. Fassan, G. De Maglio, V. Zagonel and M. Di Maio. Clinical prognostic score of BRAF V600E mutated (BM) metastatic colorectal cancer (mCRC): Results from the "BRAF, BeCool" platform. J Clin Oncol 36, 2018 (suppl 4S; abstr 639).

- 6) D. Rossini, C. Cremolini, E. Conca, M. Del Re, A. Busico, F. Pietrantonio, F. Bergamo, R. Danesi, M. Casagrande, E. Tamburini, E. Dell'Aquila, A. Strippoli, G. Masi, G. Tonini, F. Negri, D. C. Corsi, P. Ermacora, **R. Intini**, A. Falcone, D. Santini. Liquid biopsy to predict benefit from rechallenge with cetuximab (cet) + irinotecan (iri) in RAS/BRAF wild-type metastatic colorectal cancer patients (pts) with acquired resistance to first-line cet+iri: Final results and translational analyses of the CRICKET study by GONO. *J Clin Oncol* 36, 2018 (suppl; abstr 12007)
- 7) V. Dadduzio, M.D. Rizzato, G. Ramondo, C. Vivaldi, M. Milella, G. Brandi, S. Cereda, S. Murgioni, G.G. Cardellino, R. Filippi, D. Santini, G. Pasquini, **R. Intini**, V. Vaccaro, A. Palloni, M. Reni, G. Musettini, E. Gringeri, C. Alberti, V. Zagonel. Advanced intrahepatic cholangiocarcinoma (iCCA) treated with arterial-directed therapies (ADT): Outcomes and safety from a multicenter Italian experience. *Annals of Oncology* 29, 2018 (suppl_8).

I authorize the treatment of my personal data according to the Italian law 196/2003